Gain Therapeutics, Inc.
GANX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001819411
No open-market purchases or sales by Gain Therapeutics, Inc. insiders were filed in the last 90 days; 50 institutions reported holding it in 13F filings for Q2 2026, worth $17.4M in total; Greenlight Capital is the only superinvestor holding it.
13F holders, Q2 2023
Institutional positions in Gain Therapeutics, Inc. as of Jun 30, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 24
- +2 vs. Q1 2023
- Shares held
- 1.27M
- +118.2K (+10.3%) vs. Q1 2023
- Total value
- $5.68M
- +$134.4K (+2.4%) vs. Q1 2023
- New holders
- 4
- 11 more added
- Sold out
- 2
- 3 more reduced
Compare with Q1 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting GANX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 50 | $17.4M |
| Q1 2026 | 42 | $15.8M |
| Q4 2025 | 48 | $25.9M |
| Q3 2025 | 38 | $7.70M |
| Q2 2025 | 35 | $6.49M |
| Q1 2025 | 33 | $5.07M |
| Q4 2024 | 25 | $3.94M |
| Q3 2024 | 19 | $2.40M |
| Q2 2024 | 28 | $3.89M |
| Q1 2024 | 26 | $7.04M |
| Q4 2023 | 24 | $5.05M |
| Q3 2023 | 24 | $4.95M |
| Q2 2023 | 24 | $5.68M |
| Q1 2023 | 22 | $5.54M |
| Q4 2022 | 21 | $3.78M |
| Q3 2022 | 23 | $3.95M |
| Q2 2022 | 16 | $3.87M |
| Q1 2022 | 16 | $4.75M |
| Q4 2021 | 19 | $5.71M |
| Q3 2021 | 14 | $6.65M |
| Q2 2021 | 14 | $8.95M |
| Q1 2021 | 12 | $15.0M |
Institutions, Q2 2023
Shares, value and share of portfolio for each institution holding Gain Therapeutics, Inc.; share changes are against Q1 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Greenlight Capital Inc | 546,560 | $2.45M | 0.11% | 00.0% | Unchanged |
| Geode Capital Management, LLC | 138,721 | $621.5K | 0.00% | +44,514+47.3% | Added |
| CM Management, LLC | 90,000 | $403.0K | 0.39% | 00.0% | Unchanged |
| Susquehanna International Group, LLP | 69,790 | $312.7K | 0.00% | +54,618+360.0% | Added |
| Vanguard Group Inc | 64,118 | $287.2K | 0.00% | +11,513+21.9% | Added |
| Prelude Capital Management, LLC | 58,100 | $260.3K | 0.02% | 00.0% | Unchanged |
| Renaissance Technologies LLC | 47,600 | $213.0K | 0.00% | +8,900+23.0% | Added |
| Bridgeway Capital Management, LLC | 46,100 | $206.5K | 0.00% | −13,900−23.2% | Reduced |
| Citadel Advisors LLC | 36,247 | $162.4K | 0.00% | +18,800+107.8% | Added |
| Raymond James & Associates | 33,400 | $149.6K | 0.00% | +13,400+67.0% | Added |
| BlackRock Inc. | 29,024 | $130.0K | 0.00% | +4,246+17.1% | Added |
| Dimensional Fund Advisors LP | 20,962 | $93.9K | 0.00% | +2,355+12.7% | Added |
| Royal Bank of Canada | 20,046 | $90.0K | 0.00% | −18,954−48.6% | Reduced |
| Northern Trust Corp | 13,277 | $59.5K | 0.00% | 00.0% | Unchanged |
| Millennium Management LLC | 12,562 | $56.3K | 0.00% | +12,562 | New |
| GWM Advisors LLC | 11,050 | $49.5K | 0.00% | +550+5.2% | Added |
| Advisor Group Holdings, Inc. | 10,000 | $44.8K | 0.00% | 00.0% | Unchanged |
| UBS Group AG | 9,447 | $42.3K | 0.00% | +5,142+119.4% | Added |
| Tower Research Capital LLC (TRC) | 4,347 | $19.5K | 0.00% | −2,497−36.5% | Reduced |
| Wells Fargo & Company | 3,718 | $16.7K | 0.00% | +5+0.1% | Added |
| HM Payson & Co | 1,000 | $4.48K | 0.00% | +1,000 | New |
| Group One Trading, L.P. | 847 | $3.79K | 0.00% | +847 | New |
| Morgan Stanley | 800 | $3.58K | 0.00% | 00.0% | Unchanged |
| JPMorgan Chase & Co | 6 | $27 | 0.00% | +6 | New |
| Wealth Alliance Advisory Group, LLC | 0 | $0 | 0.00% | −12,502−100.0% | Sold out |
| Cannell Capital LLC | 0 | $0 | 0.00% | −12,371−100.0% | Sold out |